BioCryst Pharmaceuticals
BCRX
BCRX
115 hedge funds and large institutions have $283M invested in BioCryst Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 35 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
115
Holders Change
-1
Holders Change %
-0.86%
% of All Funds
2.53%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
16
Increased
37
Reduced
35
Closed
17
Calls
$1.02M
Puts
$185K
Net Calls
+$838K
Net Calls Change
+$858K
Top Buyers
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
$7.95M |
| 2 |
Invesco
Atlanta,
Georgia
|
$0 |
| 3 |
State Street
Boston,
Massachusetts
|
$13.9M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
$36.5M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
$2.61M |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
PCM
126
Prelude Capital Management
New York
| – | -$14K | -3,587 | Closed |
|
|
CG
127
Cutler Group
San Francisco,
California
| – | -$9K | -2,400 | Closed |
|
|
MAM
128
Meeder Asset Management
Dublin,
Ohio
| – | -$8K | -2,214 | Closed |
|
129
ClearBridge Investments
New York
| – | -$5K | -1,207 | Closed |
|